Last reviewed · How we verify

PANCRECARB® (pancrelipase)

Digestive Care, Inc. · Phase 3 active Small molecule

PANCRECARB® (pancrelipase) is a Pancreatic enzyme replacement therapy Small molecule drug developed by Digestive Care, Inc.. It is currently in Phase 3 development for Exocrine pancreatic insufficiency due to chronic pancreatitis, Exocrine pancreatic insufficiency due to cystic fibrosis, Exocrine pancreatic insufficiency due to pancreatic surgery or obstruction. Also known as: MS-16.

Pancrelipase is a pancreatic enzyme replacement therapy that supplies lipase, protease, and amylase to aid digestion of fats, proteins, and carbohydrates in patients with pancreatic insufficiency.

Pancrelipase is a pancreatic enzyme replacement therapy that supplies lipase, protease, and amylase to aid digestion of fats, proteins, and carbohydrates in patients with pancreatic insufficiency. Used for Exocrine pancreatic insufficiency due to chronic pancreatitis, Exocrine pancreatic insufficiency due to cystic fibrosis, Exocrine pancreatic insufficiency due to pancreatic surgery or obstruction.

At a glance

Generic namePANCRECARB® (pancrelipase)
Also known asMS-16
SponsorDigestive Care, Inc.
Drug classPancreatic enzyme replacement therapy
ModalitySmall molecule
Therapeutic areaGastroenterology
PhasePhase 3

Mechanism of action

Pancrelipase contains a mixture of pancreatic enzymes (lipase, protease, and amylase) derived from porcine pancreatic tissue. In patients with exocrine pancreatic insufficiency, the pancreas cannot produce sufficient enzymes to properly digest food, leading to malabsorption. Pancrelipase supplements these missing enzymes to restore normal digestive function and nutrient absorption.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about PANCRECARB® (pancrelipase)

What is PANCRECARB® (pancrelipase)?

PANCRECARB® (pancrelipase) is a Pancreatic enzyme replacement therapy drug developed by Digestive Care, Inc., indicated for Exocrine pancreatic insufficiency due to chronic pancreatitis, Exocrine pancreatic insufficiency due to cystic fibrosis, Exocrine pancreatic insufficiency due to pancreatic surgery or obstruction.

How does PANCRECARB® (pancrelipase) work?

Pancrelipase is a pancreatic enzyme replacement therapy that supplies lipase, protease, and amylase to aid digestion of fats, proteins, and carbohydrates in patients with pancreatic insufficiency.

What is PANCRECARB® (pancrelipase) used for?

PANCRECARB® (pancrelipase) is indicated for Exocrine pancreatic insufficiency due to chronic pancreatitis, Exocrine pancreatic insufficiency due to cystic fibrosis, Exocrine pancreatic insufficiency due to pancreatic surgery or obstruction.

Who makes PANCRECARB® (pancrelipase)?

PANCRECARB® (pancrelipase) is developed by Digestive Care, Inc. (see full Digestive Care, Inc. pipeline at /company/digestive-care-inc).

Is PANCRECARB® (pancrelipase) also known as anything else?

PANCRECARB® (pancrelipase) is also known as MS-16.

What drug class is PANCRECARB® (pancrelipase) in?

PANCRECARB® (pancrelipase) belongs to the Pancreatic enzyme replacement therapy class. See all Pancreatic enzyme replacement therapy drugs at /class/pancreatic-enzyme-replacement-therapy.

What development phase is PANCRECARB® (pancrelipase) in?

PANCRECARB® (pancrelipase) is in Phase 3.

What are the side effects of PANCRECARB® (pancrelipase)?

Common side effects of PANCRECARB® (pancrelipase) include Abdominal pain, Nausea, Diarrhea, Constipation, Hyperuricemia.

Related